| Recruiting | Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or NCT07402915 | AstraZeneca | Phase 1 |
| Recruiting | Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resista NCT06856499 | University of Colorado, Denver | Phase 1 |
| Recruiting | A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine NCT06890338 | AbbVie | Phase 2 |
| Not Yet Recruiting | Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tu NCT07044349 | Beijing Biostar Pharmaceuticals Co., Ltd. | Phase 2 |
| Recruiting | A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant NCT06994195 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers NCT07024784 | AbbVie | Phase 2 |
| Recruiting | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adju NCT06915025 | Imunon | Phase 3 |
| Not Yet Recruiting | Surgery for Relapsed Ovarian Cancer in Precision NCT06602063 | Shanghai Gynecologic Oncology Group | Phase 1 / Phase 2 |
| Recruiting | Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer NCT06787612 | Regeneron Pharmaceuticals | Phase 2 |
| Recruiting | Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer NCT07023484 | The University of Hong Kong | Phase 2 |
| Withdrawn | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Vari NCT04889495 | Pfizer | — |
| Recruiting | The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During I NCT07460180 | The Netherlands Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers NCT06906341 | Corcept Therapeutics | Phase 2 |
| Active Not Recruiting | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors NCT06714617 | SystImmune Inc. | Phase 1 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus NCT06824467 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Prim NCT06834672 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 |
| Recruiting | Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer NCT06617923 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Withdrawn | A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer NCT06545617 | Bio-Thera Solutions | Phase 1 / Phase 2 |
| Recruiting | Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer NCT06735326 | Qilu Hospital of Shandong University | Phase 2 |
| Recruiting | CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. NCT06690775 | TORL Biotherapeutics, LLC | Phase 2 |
| Recruiting | A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Plati NCT05460000 | North Eastern German Society of Gynaecological Oncology | Phase 2 |
| Active Not Recruiting | Diet, Hepcidin, and Chemotherapy RDI NCT06483997 | George Washington University | — |
| Recruiting | A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in NCT06469281 | Regeneron Pharmaceuticals | Phase 1 |
| Active Not Recruiting | Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer NCT06342986 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients NCT06007586 | Sichuan Cancer Hospital and Research Institute | Phase 3 |
| Recruiting | Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker Test NCT06445621 | Uppsala University Hospital | — |
| Recruiting | Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer NCT07022535 | The University of Hong Kong | Phase 2 |
| Active Not Recruiting | A Study of Sovilnesib in Subjects With Ovarian Cancer NCT06084416 | Volastra Therapeutics, Inc. | Phase 1 |
| Recruiting | Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy NCT06024109 | Aesculap AG | — |
| Recruiting | Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surg NCT06290193 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal NCT06173037 | RemeGen Co., Ltd. | Phase 2 |
| Active Not Recruiting | Nudge to Gynecologic Oncology NCT06451263 | Abramson Cancer Center at Penn Medicine | N/A |
| Recruiting | HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer NCT06014190 | Hansoh BioMedical R&D Company | Phase 2 |
| Unknown | Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARP NCT06161272 | Guangxi Medical University | Phase 2 |
| Not Yet Recruiting | First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer NCT06063070 | Sun Yat-sen University | Phase 2 |
| Recruiting | An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib NCT05887609 | University of Colorado, Denver | Phase 2 |
| Unknown | MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer NCT05960630 | Royal Surrey County Hospital NHS Foundation Trust | N/A |
| Completed | Choices About Genetic Testing And Learning Your Risk With Smart Technology NCT06184867 | Rutgers, The State University of New Jersey | N/A |
| Recruiting | Study of AVZO-021 in Patients With Advanced Solid Tumors NCT05867251 | Avenzo Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Cho NCT05870748 | Sutro Biopharma, Inc. | Phase 2 / Phase 3 |
| Active Not Recruiting | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors NCT05858736 | OncoC4, Inc. | Phase 1 |
| Recruiting | Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or Hig NCT05080556 | University College, London | Phase 2 |
| Terminated | A Biomarker Screening Protocol for Participants With Solid Tumors NCT05891197 | Lyell Immunopharma, Inc. | — |
| Completed | A Study of CDX-585 in Patients With Advanced Malignancies NCT05788484 | Celldex Therapeutics | Phase 1 |
| Unknown | Huaier Granule in Patients With Stage I Primary Ovarian Fallopian Tube Cancer After Peritoneal Cancer NCT05792254 | Ruijin Hospital | N/A |
| Terminated | MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer NCT05708924 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Ep NCT06087289 | Novakand Pharma AB | Phase 1 / Phase 2 |
| Recruiting | ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer NCT05071937 | Alexander B Olawaiye, MD | Phase 2 |
| Recruiting | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial NCT05445778 | AbbVie | Phase 3 |
| Unknown | Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PA NCT05065021 | University Health Network, Toronto | Phase 2 |
| Recruiting | Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian NCT05739981 | Imunon | Phase 1 / Phase 2 |
| Active Not Recruiting | First in Human Study of IMGN151 in Recurrent Gynaecological Cancers NCT05527184 | AbbVie | Phase 1 |
| Active Not Recruiting | ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer NCT05446298 | OncoC4, Inc. | Phase 2 |
| Terminated | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary NCT05538624 | Avenge Bio, Inc | Phase 1 / Phase 2 |
| Recruiting | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366 | Genmab | Phase 1 / Phase 2 |
| Unknown | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer NCT05801783 | Shanghai Yunying Medical Technology | EARLY_Phase 1 |
| Recruiting | Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype NCT05574673 | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | — |
| Unknown | A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer NCT05043402 | OncXerna Theraputics, Inc. | Phase 3 |
| Recruiting | Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer NCT04701645 | Brigham and Women's Hospital | Phase 1 |
| Unknown | Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma NCT05665023 | Yonsei University | Phase 2 |
| Recruiting | Development and Management of Registry in Patients With Gynecologic Cancer in Korea NCT05912972 | Asan Medical Center | — |
| Active Not Recruiting | Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expr NCT05456685 | AbbVie | Phase 2 |
| Recruiting | Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovaria NCT05009082 | AGO Study Group | Phase 3 |
| Withdrawn | SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care NCT04368130 | Dana-Farber Cancer Institute | N/A |
| Recruiting | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherap NCT05281471 | Genelux Corporation | Phase 3 |
| Completed | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers NCT05483933 | Shattuck Labs, Inc. | Phase 1 |
| Unknown | A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian C NCT05622890 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | A Study of XMT-1660 in Participants With Solid Tumors NCT05377996 | Mersana Therapeutics | Phase 1 |
| Terminated | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer NCT05261490 | Pfizer | Phase 1 / Phase 2 |
| Recruiting | Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer NCT05200260 | Shanghai Gynecologic Oncology Group | Phase 2 |
| Terminated | Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) NCT05329545 | Mersana Therapeutics | Phase 3 |
| Recruiting | A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) NCT05429970 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectom NCT05287451 | M.D. Anderson Cancer Center | N/A |
| Terminated | A Study to Investigate LYL797 in Adults With Solid Tumors NCT05274451 | Lyell Immunopharma, Inc. | Phase 1 |
| Terminated | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in NCT05200364 | Sutro Biopharma, Inc. | Phase 1 |
| Active Not Recruiting | Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian NCT04575961 | North Eastern German Society of Gynaecological Oncology | Phase 2 |
| Recruiting | Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer NCT05236686 | Shanghai Gynecologic Oncology Group | N/A |
| Completed | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer NCT05198804 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Terminated | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithe NCT05092360 | Mural Oncology, Inc | Phase 3 |
| Active Not Recruiting | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies NCT05199272 | 23andMe, Inc. | Phase 1 / Phase 2 |
| Recruiting | Using Aspirin to Improve Immunological Features of Ovarian Tumors NCT05080946 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Unknown | Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma NCT05537844 | Liz-Anne Lewsley | — |
| Completed | Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers NCT05041257 | AbbVie | Phase 2 |
| Terminated | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) NCT05001282 | Elucida Oncology | Phase 1 / Phase 2 |
| Terminated | A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy NCT04814875 | THERAPIM PTY LTD | Phase 1 / Phase 2 |
| Unknown | Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC NCT04983550 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 |
| Recruiting | A Beta-only IL-2 ImmunoTherapY Study NCT05086692 | Medicenna Therapeutics, Inc. | Phase 1 / Phase 2 |
| Withdrawn | DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma NCT03905902 | SOTIO a.s. | Phase 3 |
| Withdrawn | Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer NCT04510584 | University Health Network, Toronto | Phase 2 |
| Unknown | A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer NCT04846842 | Lee's Pharmaceutical Limited | Phase 2 |
| Withdrawn | Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, NCT03607955 | Washington University School of Medicine | Phase 1 |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Completed | Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, Hig NCT04991051 | AstraZeneca | — |
| Unknown | Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary P NCT04375956 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 2 |
| Terminated | BrUOG 390: Neoadjuvant Treatment With Talazoparib NCT04598321 | Brown University | Phase 1 |
| Completed | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib NCT04676334 | pharmaand GmbH | Phase 3 |
| Recruiting | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors NCT04657068 | Artios Pharma Ltd | Phase 1 / Phase 2 |
| Not Yet Recruiting | Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) NCT04515602 | Shanghai Gynecologic Oncology Group | Phase 3 |
| Recruiting | A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplima NCT04590326 | Regeneron Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer NCT04516447 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Phase 1 |
| Active Not Recruiting | Tempus Priority Study: A Pan-tumor Observational Study NCT05179824 | Tempus AI | — |
| Terminated | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal NCT03924245 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Completed | Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer NCT04546373 | Grupo Español de Investigación en Cáncer de Ovario | — |
| Terminated | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors NCT04442126 | Numab Therapeutics AG | Phase 1 / Phase 2 |
| Completed | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies NCT04440943 | Celldex Therapeutics | Phase 1 |
| Completed | Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO St NCT04539327 | Grupo Español de Investigación en Cáncer de Ovario | — |
| Completed | A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Pe NCT04296890 | ImmunoGen, Inc. | Phase 3 |
| Active Not Recruiting | Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer NCT05220033 | Rutgers, The State University of New Jersey | N/A |
| Completed | KORE-INNOVATION: a Prospective, Multi-site Clinical Trial to Implement and Analyse the Effects of an Innovativ NCT05256576 | Charite University, Berlin, Germany | N/A |
| Completed | Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer NCT04406623 | Shattuck Labs, Inc. | Phase 1 |
| Unknown | Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival NCT04402333 | Royal Surrey County Hospital NHS Foundation Trust | — |
| Completed | Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ova NCT04227522 | North Eastern German Society of Gynaecological Oncology | Phase 3 |
| Unknown | A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer F NCT04229615 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Unknown | Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR NCT04295577 | Royal Marsden NHS Foundation Trust | — |
| Completed | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Adv NCT04209855 | AbbVie | Phase 3 |
| Unknown | High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy NCT04201561 | Seoul National University Hospital | Phase 3 |
| Active Not Recruiting | Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy NCT04204811 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | A Trial Evaluating TG4050 in Ovarian Carcinoma. NCT03839524 | Transgene | Phase 1 |
| Completed | Genomic BRCA and Extensive ovArian Cancer Testing NCT04027868 | ARCAGY/ GINECO GROUP | — |
| Terminated | Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer) NCT03891576 | Mario Negri Institute for Pharmacological Research | Phase 2 |
| Completed | The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer NCT03921658 | University of Minnesota | — |
| Recruiting | Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) NCT03983226 | Shanghai Gynecologic Oncology Group | Phase 2 |
| Unknown | Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery NCT03373058 | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Phase 3 |
| Terminated | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers NCT04025216 | Kite, A Gilead Company | Phase 1 |
| Terminated | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) NCT03824704 | pharmaand GmbH | Phase 2 |
| Completed | Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer Patients NCT04537702 | Duke University | N/A |
| Unknown | A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritone NCT04029909 | Lee's Pharmaceutical Limited | Phase 1 |
| Completed | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tum NCT03849469 | Xencor, Inc. | Phase 1 |
| Unknown | Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritonea NCT03430700 | University College, London | Phase 2 |
| Active Not Recruiting | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors NCT03872947 | Toray Industries, Inc | Phase 1 |
| Completed | Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian T NCT06274541 | Cancer Trials Ireland | — |
| Completed | A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (in NCT03657043 | Seagen Inc. | Phase 2 |
| Unknown | HIPEC After Initial CRS in Patients Who Have Received NACT NCT03540017 | Northwell Health | Phase 1 |
| Active Not Recruiting | Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube NCT03771651 | University of Oklahoma | EARLY_Phase 1 |
| Completed | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Canc NCT03748186 | Sutro Biopharma, Inc. | Phase 1 |
| Completed | Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer NCT03759587 | Takeda | Phase 2 |
| Completed | Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer NCT03759600 | Takeda | Phase 2 |
| Unknown | Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Periton NCT03693248 | Seoul National University Hospital | Phase 3 |
| Active Not Recruiting | Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the Fir NCT03740165 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer NCT03783949 | Universitaire Ziekenhuizen KU Leuven | Phase 2 |
| Terminated | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors NCT03621982 | ADC Therapeutics S.A. | Phase 1 |
| Terminated | MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Perito NCT03585764 | University of Pennsylvania | Phase 1 |
| Completed | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (o NCT03648489 | Imperial College London | Phase 2 |
| Active Not Recruiting | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) NCT03393884 | Imunon | Phase 1 / Phase 2 |
| Completed | Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of M NCT03593681 | Boston Scientific Corporation | — |
| Completed | A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated NCT03635489 | Hoffmann-La Roche | Phase 3 |
| Unknown | BEACON - ABC in Recurrent Platinum Resistant HGSOC NCT03363867 | Peter MacCallum Cancer Centre, Australia | Phase 2 |
| Completed | Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers NCT03604653 | Holy Name Medical Center, Inc. | — |
| Active Not Recruiting | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Respo NCT03522246 | pharmaand GmbH | Phase 3 |
| Active Not Recruiting | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas NCT03355976 | Brown University | Phase 2 |
| Unknown | PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Can NCT03283943 | British Columbia Cancer Agency | Phase 1 |
| Unknown | Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian NCT03180177 | Shu-Zhong Cui | Phase 3 |
| Active Not Recruiting | Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Periton NCT03029403 | University Health Network, Toronto | Phase 2 |
| Unknown | Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients NCT03321188 | Andrea Jewell | Phase 2 |
| Terminated | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Ad NCT03311334 | Sumitomo Pharma America, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies NCT03329950 | Celldex Therapeutics | Phase 1 |
| Terminated | Anti-PD-L1 and SAbR for Ovarian Cancer NCT03312114 | University of Texas Southwestern Medical Center | Phase 2 |
| Completed | Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer NCT03126812 | The Netherlands Cancer Institute | Phase 1 / Phase 2 |
| Completed | Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int NCT03213964 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | The Treatment Preferences of Women Diagnosed With Ovarian Cancer NCT03367260 | Duke University | — |
| Unknown | Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiat NCT03188159 | National University Hospital, Singapore | Phase 2 |
| Completed | Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Can NCT03056833 | Ronald Buckanovich | Phase 1 |
| Terminated | Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors NCT03189108 | National Cancer Institute (NCI) | — |
| Completed | CAR T Cells in Mesothelin Expressing Cancers NCT03054298 | University of Pennsylvania | Phase 1 |
| Completed | Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab NCT03093155 | Yale University | Phase 2 |
| Completed | Homologous Recombination Inquiry Through Ovarian Malignancy Investigations NCT03159572 | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | — |
| Unknown | Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia NCT04001023 | Turku University Hospital | N/A |
| Completed | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Partici NCT03038100 | Hoffmann-La Roche | Phase 3 |
| Completed | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Ca NCT02855944 | pharmaand GmbH | Phase 3 |
| Terminated | Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interfer NCT02948426 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). NCT02834975 | University of Miami | Phase 2 |
| Completed | Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer NCT02915523 | Syndax Pharmaceuticals | Phase 1 / Phase 2 |
| Active Not Recruiting | Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery NCT02884648 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib NCT02873962 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer NCT02973750 | H. Lee Moffitt Cancer Center and Research Institute | — |
| Completed | Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitati NCT02928549 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer NCT02865811 | Dana-Farber Cancer Institute | Phase 2 |
| Withdrawn | HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcin NCT02487849 | Krankenhaus Barmherzige Schwestern Linz | Phase 2 |
| Active Not Recruiting | Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) NCT02859038 | Shanghai Gynecologic Oncology Group | Phase 3 |
| Unknown | HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life NCT03000192 | University Hospital Southampton NHS Foundation Trust | — |
| Unknown | A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cance NCT02489006 | University Health Network, Toronto | Phase 2 |
| Terminated | A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer NCT02661815 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers NCT02725489 | Mary Crowley Medical Research Center | Phase 2 |
| Completed | A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers NCT02824328 | Duke University | — |
| Completed | A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers NCT02728830 | AA Secord | EARLY_Phase 1 |
| Completed | GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer NCT02759588 | Genelux Corporation | Phase 1 / Phase 2 |
| Completed | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer NCT02657889 | Tesaro, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor ( NCT02631876 | ImmunoGen, Inc. | Phase 3 |
| Completed | Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubic NCT02606305 | ImmunoGen, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer NCT02571725 | New Mexico Cancer Research Alliance | Phase 1 / Phase 2 |
| Unknown | Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer NCT02534922 | Oncolix, Inc. | Phase 1 |
| Completed | A Study of Long-Term Responders on Olaparib NCT02489058 | University Health Network, Toronto | — |
| Completed | LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer NCT02668913 | Geoff Hall | N/A |
| Unknown | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies NCT02433626 | Critical Outcome Technologies Inc. | Phase 1 |
| Completed | Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients NCT02470299 | New Mexico Cancer Research Alliance | N/A |
| Completed | Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian C NCT02480374 | Imunon | Phase 1 |
| Unknown | Total/Subtotal Colectomy in Ovarian Cancer NCT02595021 | Shanghai Gynecologic Oncology Group | Phase 2 |
| Unknown | p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Ca NCT02435186 | Shenzhen SiBiono GeneTech Co.,Ltd | Phase 2 |
| Terminated | Autologous OC-L Vaccine and Ovarian Cancer NCT02452775 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission NCT02324439 | Southern Illinois University | Phase 1 |
| Terminated | Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer NCT02278783 | University of Utah | Phase 2 |
| Active Not Recruiting | "Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Ca NCT01883297 | University Health Network, Toronto | Phase 1 |
| Completed | Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other NCT02262455 | Santa Maria Biotherapeutics | Phase 1 |
| Completed | Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer NCT01610869 | University College, London | Phase 2 |
| Terminated | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer NCT02012192 | Medical University Innsbruck | Phase 1 / Phase 2 |
| Unknown | Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage NCT03150121 | Sheba Medical Center | N/A |
| Completed | Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib f NCT02121990 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid NCT01968213 | pharmaand GmbH | Phase 3 |
| Active Not Recruiting | HOT: HIPEC in Ovarian Cancer as Initial Treatment NCT02124421 | Mercy Medical Center | Phase 2 |
| Completed | The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer NCT01556841 | University College, London | Phase 2 |
| Terminated | Tivozanib As Maintenance Therapy In GYN NCT01972516 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian T NCT01891344 | pharmaand GmbH | Phase 2 |
| Completed | PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer NCT01899599 | Glycotope GmbH | Phase 2 |
| Completed | Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Canc NCT03332576 | ImmunoVaccine Technologies, Inc. (IMV Inc.) | Phase 1 |
| Completed | Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients NCT01905163 | Centre Jean Perrin | Phase 2 |
| Completed | BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer NCT01669798 | AA Secord | Phase 2 |
| Completed | Accelerating Gastrointestinal Recovery NCT01704651 | Jamie N. Bakkum-Gamez | Phase 3 |
| Withdrawn | 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant NCT01766622 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Completed | VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian NCT01666444 | Celgene | Phase 2 |
| Terminated | Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer NCT01744821 | Northwestern University | N/A |
| Completed | Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer NCT03480750 | National Cheng-Kung University Hospital | Phase 1 / Phase 2 |
| Completed | A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cance NCT01610206 | Linda R Duska | Phase 2 |
| Withdrawn | Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer NCT01661868 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Interactive Educational Website for Women With Ovarian Cancer & Caregivers NCT01626014 | University of Minnesota | EARLY_Phase 1 |
| Completed | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian NCT01402271 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 1 / Phase 2 |
| Completed | A Study LY2228820 for Recurrent Ovarian Cancer NCT01663857 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Completed | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer NCT01649336 | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 |
| Completed | Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer NCT01591772 | Memorial Sloan Kettering Cancer Center | — |
| Completed | CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer NCT01652079 | Massachusetts General Hospital | Phase 2 |
| Terminated | A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy NCT01659554 | Columbia University | Phase 2 |
| Completed | Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer NCT01670799 | New Mexico Cancer Research Alliance | EARLY_Phase 1 |
| Terminated | TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovari NCT01493505 | Amgen | Phase 3 |
| Completed | Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cance NCT01416038 | ImmunoVaccine Technologies, Inc. (IMV Inc.) | Phase 1 |
| Completed | Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer NCT01471483 | Memorial Sloan Kettering Cancer Center | — |
| Completed | A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phas NCT01482715 | pharmaand GmbH | Phase 1 / Phase 2 |
| Completed | A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers NCT01447706 | Merrimack Pharmaceuticals | Phase 2 |
| Completed | Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer NCT01442051 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | A Survivorship Care Plan for Gynaecological Cancer Patients NCT01582906 | Royal Marsden NHS Foundation Trust | — |
| Completed | Validation of a Nutrition Screening Tool NCT01851928 | Royal Marsden NHS Foundation Trust | — |
| Completed | Search for Predictors of Therapeutic Response in Ovarian Carcinoma NCT01391351 | Centre Francois Baclesse | N/A |
| Completed | Pelvic Floor Disorders in Survivors of Gynecologic Malignancies NCT01370122 | Abramson Cancer Center at Penn Medicine | — |
| Completed | Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer NCT01220154 | David O'Malley | Phase 1 |
| Terminated | AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) NCT01281254 | Amgen | Phase 3 |
| Terminated | A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Pri NCT01312389 | Abramson Cancer Center at Penn Medicine | Phase 1 / Phase 2 |
| Terminated | Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer NCT01137071 | Recepta Biopharma | Phase 2 |
| Completed | Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer NCT01196741 | University College, London | Phase 2 / Phase 3 |
| Terminated | Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer NCT01312376 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers NCT01237067 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Panitumumab and Gemcitabine in Relapsed Ovarian Cancer NCT01296035 | Women and Infants Hospital of Rhode Island | Phase 2 |
| Completed | Phase II ABT-888 With Cyclophosphamide NCT01306032 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer NCT01196559 | The Catholic University of Korea | Phase 2 |
| Completed | Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive NCT01262040 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer NCT01281514 | Fox Chase Cancer Center | Phase 1 |
| Completed | Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer NCT01253681 | Amgen | Phase 1 |
| Completed | TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for NCT01204749 | Amgen | Phase 3 |
| Completed | Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With NCT01248962 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian NCT01219777 | Ritu Salani | Phase 1 |
| Completed | Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer NCT01031381 | University of Pittsburgh | Phase 2 |
| Completed | Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer NCT01188876 | Massachusetts General Hospital | Phase 1 / Phase 2 |
| Completed | Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gas NCT01216813 | Royal Marsden NHS Foundation Trust | — |
| Completed | Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients NCT01308944 | Washington University School of Medicine | Phase 1 |
| Terminated | WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer NCT01144442 | Masonic Cancer Center, University of Minnesota | N/A |
| Completed | Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Canc NCT01166737 | AGO Study Group | N/A |
| Completed | Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer NCT01105650 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Neoadjuvant Therapy for Ovarian Cancer NCT01146795 | Jason D. Wright | Phase 2 |
| Completed | Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial NCT01506856 | Gynecologic Oncology Trial & Investigation Consortium | Phase 2 / Phase 3 |
| Completed | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Stud NCT01091428 | Millennium Pharmaceuticals, Inc. | Phase 2 |
| Completed | Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer NCT00993655 | Canadian Cancer Trials Group | Phase 2 |
| Terminated | Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor NCT01096381 | Vanderbilt-Ingram Cancer Center | — |
| Completed | S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epitheli NCT00872989 | SWOG Cancer Research Network | Phase 2 |
| Unknown | A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, R NCT01570582 | Korean Gynecologic Oncology Group | Phase 2 |
| Completed | Irinotecan and Bevacizumab for Recurrent Ovarian Cancer NCT01091259 | NYU Langone Health | Phase 2 |
| Terminated | Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer NCT01083537 | University Health Network, Toronto | Phase 1 / Phase 2 |
| Unknown | Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, NCT01074398 | Gynecologic Oncology Group | — |
| Completed | AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies NCT01065662 | Susana M. Campos, MD | Phase 1 |
| Terminated | Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarc NCT01035658 | SCRI Development Innovations, LLC | Phase 1 / Phase 2 |
| Completed | Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallop NCT00993616 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy fo NCT01170299 | Royal Marsden NHS Foundation Trust | N/A |
| Active Not Recruiting | Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT NCT01276574 | Turku University Hospital | — |
| Completed | Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143) NCT00959582 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Ca NCT01048814 | Precision Therapeutics | — |
| Unknown | Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With NCT01100372 | Medical University Innsbruck | Phase 2 |
| Terminated | Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer NCT00910000 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Completed | Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignan NCT01079832 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Can NCT00903630 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Completed | First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer NCT01669226 | Shanghai Gynecologic Oncology Group | Phase 2 |
| Completed | Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health NCT00870233 | Memorial Sloan Kettering Cancer Center | — |
| Terminated | Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer NCT00866723 | Beth Israel Deaconess Medical Center | Phase 2 |
| Completed | Study of Paclitaxel in Patients With Ovarian Cancer NCT00989131 | Oasmia Pharmaceutical AB | Phase 3 |
| Completed | Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery NCT00842452 | Steven Waggoner, MD | Phase 1 |
| Completed | Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies NCT00856180 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial O NCT00770536 | Amgen | Phase 1 |
| Completed | Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer NCT00850772 | Queensland Centre for Gynaecological Cancer | Phase 3 |
| Completed | Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube NCT00692900 | University of Pittsburgh | Phase 1 |
| Completed | Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers NCT00803569 | Ludwig Institute for Cancer Research | Phase 1 |
| Completed | Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma NCT00768144 | Dana-Farber Cancer Institute | Phase 2 |
| Suspended | A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal NCT00753480 | Genentech, Inc. | Phase 1 |
| Completed | Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fal NCT00801320 | Beth Israel Deaconess Medical Center | N/A |
| Completed | Study of Ramucirumab in Ovarian Cancer NCT00721162 | Eli Lilly and Company | Phase 2 |
| Active Not Recruiting | Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colo NCT00799110 | Beth Israel Deaconess Medical Center | Phase 2 |